All Blogs
Oct 01, 2026
UTR Therapeutics’ UTRxMYCN M1-14 Granted FDA Orphan Drug and Rare Pediatric Disease Designations; Medtronic Announces Regulatory Milestones for New Cardiac Mapping and Ablation Software; Abbott Adds SimpleScreen™ CRC Blood Test to Colorectal Cancer Screening Portfolio; VEMERIX Introduces Patented Single-Use Ultrasound Puncture Kit With Customized Probe Compatibility; Avisi Technologies to Showcase Two-Year VisiPlate® Results at AAO Annual Meeting; FIRE1 Implants First Patient in NORM-HF Pivotal Trial for Innovative Heart Failure Management
UTR Therapeutics Inc. Announced U.S. FDA Orphan Drug Designation and Rare Pediatric Disease Designation for UTRxMYCN M1-14 On 29 September 2026, UTR Therapeutics Inc. announced that the U.S. FDA had granted Orphan Drug Designation to UTRxMYCN M1-14 for the treatment of soft tissue sarcoma, including rhabdomyosar...
Read More...
Oct 02, 2026
AQNEURSA Leads a New Chapter in Ataxia-Telangiectasia as the Pipeline Faces Its Next Test
Summary Ataxia-telangiectasia is a rare, progressive genetic disorder affecting an estimated 1 in 40,000–100,000 people worldwide. AQNEURSA received FDA approval on September 18, 2026, becoming the first and only approved treatment for ataxia in patients with ataxia-telangiectasia and marking the first...
Read More...
Sep 29, 2026
Roche Announces Positive Interim Results for Sefaxersen in IgA Nephropathy; Lilly’s Olumiant Receives FDA Approval for Pediatric Patients With Severe Alopecia Areata; AbbVie’s JUVMO Receives U.S. FDA Approval for Parkinson’s Disease; Biologics License Application for Ifinatamab Deruxtecan Withdrawn in Extensive-Stage Small Cell Lung Cancer; Mirum Pharmaceuticals Reports Primary Endpoint Success in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
Roche Reports Positive Interim Data Showing Sefaxersen Significantly Reduces Proteinuria in IgA Nephropathy Roche announced positive prespecified interim results from the ongoing Phase III IMAgINATION study evaluating investigational sefaxersen in adults with primary IgA nephropathy (IgAN). The trial achieved it...
Read More...
Sep 30, 2026
Digital Migraine Treatment Devices: How Technology Is Rewriting the Rules of Migraine Care
Migraine has always been treated as a pill problem. Take something, wait, and hope it works before the pain peaks. Digital migraine treatment devices are quietly upending that assumption, offering people a way to interrupt an attack or prevent one from building in the first place, using electrical, magnetic, or sen...
Read More...
Sep 28, 2026
New Antimicrobial Approvals and the Fight Against Drug-Resistant Infections
Summary After years of a stalled pipeline, 2026 brought two major FDA antibiotic approvals, GSK/Spero Therapeutics’ UTEBZI (tebipenem pivoxil) and Wockhardt’s ZAYNICH (cefepime and zidebactam), signaling real progress against drug-resistant infections. Resistant bacteria are turning routine infections into m...
Read More...
Sep 25, 2026
FAYUVI’s Comeback Story: How Ultragenyx Turned Rejection Into FDA Approval
Summary On September 17, 2026, the FDA approved Ultragenyx’s FAYUVI (rebisufligene etisparvovec-hopf) as the first treatment targeting the underlying cause of Sanfilippo syndrome type A in pediatric patients with preserved neurodevelopmental function. Data from the pivotal Transpher A study and long-term fol...
Read More...
Sep 24, 2026
Powerful Medical’s AI ECG Technology Earns FDA De Novo Authorization for Heart Attack Detection; Werfen Secures US FDA 510(k) Clearance and CE Mark for Aptiva® APS IgA Reagent; Ontario Introduces Fetal Blood Type Screening to Improve Pregnancy Care; Medvue Concorde Acquires Next-Generation AI-Powered MRI System; Cardiol Therapeutics Hits Phase III MAVERIC Enrollment Target Early and Expands Pivotal Trial for CardiolRx; Ferronova Reports Preliminary MAGMAP Results in 62-Patient Gastric and Oesophageal Cancer Trial
Powerful Medical Receives FDA De Novo Authorization for AI-Based ECG Model for Acute Heart Attack Detection On 15 September 2026, Powerful Medical announced that the U.S. Food and Drug Administration had granted De Novo authorization for its Queen of Hearts ACS AI ECG Model. The AI-powered technology was d...
Read More...
Sep 23, 2026
Organ Preservation Solutions: The Silent Lifeline Between Donation and Transplantation
Every successful transplant tells two stories. The first is the one everyone sees, a patient receiving a second chance at life. The second is quieter, playing out inside a cooler or perfusion device, where a carefully engineered organ preservation solution is fighting, cell by cell, to keep a donor organ alive long...
Read More...
Sep 22, 2026
Novo’s CagriSema Shows Greater Weight Loss Than Tirzepatide in REIMAGINE 5 Trial; Telix and ITM Partner to Build a Radiopharmaceutical Powerhouse; Beacon Therapeutics Reveals Positive Topline Findings from VISTA Trial of Laru-zova for XLRP; FDA Clears Inluriyo in Combination with Verzenio for Adults with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer; IntraBio Announces FDA Approval of AQNEURSA for Ataxia-Telangiectasia
Novo’s CagriSema Demonstrates Superior Weight Loss Over Tirzepatide in REIMAGINE 5 Novo Nordisk announced topline results from the Phase 3 REIMAGINE 5 and REDEFINE 9 trials evaluating once-weekly CagriSema (cagrilintide and semaglutide), an investigational therapy and the company’s next-generation approach to we...
Read More...
Sep 21, 2026
The Semaglutide Patent Cliff: A New Challenge for Novo Nordisk and Eli Lilly
Summary Semaglutide patent expiry is staggered, not simultaneous: early wave in 2026 (India, China, Brazil, Canada, South Africa), mid wave ~2031 (UK, EU4, Japan), late wave 2032–33 (US). India and China are the biggest near-term battlegrounds, covering ~40% of the world population and a third of global obes...
Read More...